Grant: Fellowship - Priority Announcement: Gastroenterology
University of Alberta
$45,000.00
Genotype-dependent epigenetic regulation associated with cancer predisposition
FY 2014-15
Summary
One in two people develop cancer during their life. While risk factors for most cancers are known, it remains difficult to predict cancer risk for a given person. All cancers are at least partially hereditary through genetic inheritance. Regions of the human genome that are associated with increased cancer risk have already been identified for most cancer types, by studies that compare the genetic sequences of thousands of cancer patients with those of healthy people. A current priority is to pinpoint the causative 'single-letters' of genetic sequence (known as single nucleotide polymorphisms (SNPs)) within these cancer-associated genetic regions, which vary between people and affect cancer. Genetic SNPs can affect cancer risk by altering a chemical mark called DNA methylation (this is known as 'genotype-dependent methylation'), in turn switching cancer-related genes off. A relevant example is the 'MGMT' gene, where genotype-dependent methylation switches MGMT off in brain cancer, improving patient survival. By mapping genotype-dependent methylation near known cancer-associated genetic regions, within cancer patient populations, we expect to identify more example of genotype-dependent methylation that affect cancer risk. This will yield insight into the cancer biology, and will be used to pinpoint cancer-causative SNPs and the genes they affect. This information can then be used to develop tests to identify individuals at high cancer risk. We plan to carry out a systematic, genome-wide search for genotype-dependent methylation linked with cancer-associated SNPs, using custom-designed statistical methods to analyze existing 'big-data', derived from tissue samples donated by cancer patients. Identified examples of genotype-dependent methylation will then be confirmed by lab-based measurement in additional patient samples. Lab-based analyses will be used to characterize cancer-related genotype-dependent methylation and the biological mechanisms underpinning it.
Department
Program
Fellowship - Priority Announcement: Gastroenterology
Recipient
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
319703
Name
Brennan Kevin
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
Canadian Association of Gastroenterology (Oakville, Ontario); Takeda Canada Inc. (Mississauga, Ontario)
Instname2
Population and Public Health
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Genotype-dependent epigenetic regulation associated with cancer predisposition
Programtype2
Fellowship Programs
Orgnameinp2
University of Alberta
Cihramount2
$45,000
Cihrequipment2
$0
Programname2
Fellowship - Priority Announcement: Gastroenterology
Keyworddelim
Bioinformatics; Biomarkers; Biostatistics; Cancer Risk; Dna Methylation; Epigenetics; Genetics; Molecular Epidemiology; Sequencing; Transcriptional Regulation
Abstract
One in two people develop cancer during their life. While risk factors for most cancers are known, it remains difficult to predict cancer risk for a given person. All cancers are at least partially hereditary through genetic inheritance. Regions of the human genome that are associated with increased cancer risk have already been identified for most cancer types, by studies that compare the genetic sequences of thousands of cancer patients with those of healthy people. A current priority is to pinpoint the causative 'single-letters' of genetic sequence (known as single nucleotide polymorphisms (SNPs)) within these cancer-associated genetic regions, which vary between people and affect cancer. Genetic SNPs can affect cancer risk by altering a chemical mark called DNA methylation (this is known as 'genotype-dependent methylation'), in turn switching cancer-related genes off. A relevant example is the 'MGMT' gene, where genotype-dependent methylation switches MGMT off in brain cancer, improving patient survival. By mapping genotype-dependent methylation near known cancer-associated genetic regions, within cancer patient populations, we expect to identify more example of genotype-dependent methylation that affect cancer risk. This will yield insight into the cancer biology, and will be used to pinpoint cancer-causative SNPs and the genes they affect. This information can then be used to develop tests to identify individuals at high cancer risk. We plan to carry out a systematic, genome-wide search for genotype-dependent methylation linked with cancer-associated SNPs, using custom-designed statistical methods to analyze existing 'big-data', derived from tissue samples donated by cancer patients. Identified examples of genotype-dependent methylation will then be confirmed by lab-based measurement in additional patient samples. Lab-based analyses will be used to characterize cancer-related genotype-dependent methylation and the biological mechanisms underpinning it.
Competitiondate
201411
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Brennan, Kevin
Approvedterm
2 ans 0 mois
Cihrcontribution2
Inst of Nutr Metabolism &Diab~ $45,000~ $0~